Hear from some of the experts who were instrumental in developing the Accelerated mAb development program and who work with biotech companies on a daily basis to accelerate their timelines toward the production of GMP drug substances. Reduce development timelines for IgG1 and IgG4 mAbs using this established, phase-appropriate process.
An emerging biotech company sought help developing a formulation for a mAb. The company lacked in-house development expertise and wanted a partner capable of delivering an optimized formulation of buffers and excipients within an aggressive timeline and budget. Explore how we delivered an optimized formulation in three months.
Making the right decisions at the right time is crucial to the success of a biopharma executive. In this guidebook, experts share key considerations to help biopharmaceutical companies successfully advance a molecule from laboratory to clinic as quickly as possible without sacrificing product quality, process efficiency, or patient safety.
Today’s biotech landscape is highly competitive. Expediting progress from cell line development to the production of GMP drug substances for Phase 1 and Phase 2 clinical trials is essential for success. Discover how, with the Accelerated mAb Development Program, biotech companies of all sizes can reduce the time and cost to clinic with confidence.
